Deal value includes upfront payment of US$100 million with F2G eligible for additional regulatory and commercial milestones of up to US$380 million, as well as double-digit royalties on net
Deal value of up to US$525 million Novo Holdings co-led ReViral Series B financing in 2018 ReViral developing novel antiviral therapies to treat RSV infections Validation of Novo Holdings'
Novo Ventures Provides Business Update on an Exceptional Year
News provided by
Share this article
Key Numbers
39 public investments including 9 portfolio company IPOs
33 venture financings including multiple crossover financings and investments in new portfolio companies
Market leader in Europe with 13 transactions
Scott Beardsley appointed Head of Novo Ventures
Expanded team with 6 new additions bringing team total to 28
Novo Ventures, the ventures arm of Novo Holdings, today publishes its review of 2020, a year that saw significant progress across all areas of the business. For more information, please see here.
Commenting on the year, Scott Beardsley, Managing Partner of Novo Ventures, said: